New options may be possible for treatment-resistant and severe rosacea with the use of IL-17 inhibitors as researchers conduct studies on effectiveness.
Novel treatments for rosacea such as intradermal botulinum toxin-A and light therapies show promise, but more data is needed to prove their efficacy and safety in this patient population, says a recent paper.
Study suggests rosacea may be outcome of systemic inflammation with evidence linking the condition to cardiovascular disease, inflammatory bowel disease, and even some neurological diseases.
Burt's Bees skin care products may be a effective as an adjunct to prescription therapy in the management of rosacea, according to data published in the February issue of Journal of Drugs in Dermatology which was reported at the American Academy of Dermatology Annual Meeting this month.
Key developments among new and emerging treatments for acne and rosacea include a novel oral agent and a novel topical agent, as well as new formulations of existing products, says Diane S. Berson, M.D. in her presentation at AAD.
Three studies point to links between rosacea and numerous systemic comorbid diseases.
Because rosacea is an inflammatory disease there is scientific rationale for a possible association between it and other inflammatory diseases. A recent study demonstrates that rosacea patients have a greater percentage of gastrointestinal disorders than do controls and should be evaluated further if they present with GI symptoms. In such cases a systematic approach to the treatment of both conditions may be warranted.
A revised and updated set of criteria and treatment recommendations establishes a phenotype approach to diagnosing and classifying rosacea. This approach marks a transition from treating rosacea patients according to subtype. Global representation may identify research needed to determine whether rosacea is a global condition.
Keeping abreast of findings regarding the immunological, neurological and vascular roots of rosacea helps dermatologists target treatments accordingly, experts say.
Researchers analyzed messages in an online forum to understand the most vexing issues facing rosacea patients. They found tremendous confusion around available therapeutics.